Algenscribe is a pre-clinical stage biotechnology company developing a first-in-class Gene Replacement platform. The flexible platform aims to improve the efficiency and quality of Gene Editing from single bases to multi-kilobase replacements.

Algenscribe’s platform tackles technological challenges in gene editing:
1°) Boosts Efficiency: Dramatically increases gene replacement rates
2°) Enhances Precision: Minimizes nuclease-induced mutations
3°) Full-Scale Flexibility: Edits from single bases to multi-kilobase insertions
4°) Versatile Utility: Spans therapeutics and bioproduction
5°) Non-viral: Bypasses AAV-related delivery constraints.